Font Size Smaller Font Size
Larger Font Size
Latest Press Releases
-
October 11, 2018
Survey Results Presented at ECTRIMS Reveal People with Multiple Sclerosis Want More Information on Brain Atrophy
-
October 10, 2018
New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018
-
October 8, 2018
Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint
-
October 1, 2018
Celgene Corporation to Announce Third Quarter 2018 Results on October 25, 2018
-
September 12, 2018
OTEZLA® (Apremilast) Showed Meaningful Improvements in Clinical and Quality-of-Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone
No results found.